Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction ...
The Food and Drug Administration (FDA) has approved Rybrevant Faspro™, a subcutaneous (SC) formulation of amivantamab for all indications approved for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback